Cryoport, Inc. a provider of life sciences supply chain solutions, and Medipal Holdings Corp., a pharma wholesaler and distributor based in Japan, entered a multi-year strategic alliance to create an integrated regenerative medicine supply chain solution in Japan.
The companies will partner to provide integrated, end-to-end distribution solutions for specialty cell and gene therapies that demand stringent temperature control, track and trace systems and global distribution. To meet demand from the increasing number of cell and gene therapies currently in development and expected to launch in coming years, this alliance will combine both companies’ distribution services for biopharmaceutical companies in Japan and the Asia-Pacific region / worldwide.
Cryoport supports clinical trials globally, and multiple cell and gene therapies in commercial distribution. Its temperature-controlled solutions enable users to monitor shipments and track the conditions, location, and courier handling of their biologic commodities in transit around the clock. And should a problem occur that warrants intervention, Cryoport can deploy intervention capability to mitigate the situation.
MEDIPAL provides distribution solutions for specialty products in the healthcare industry across a broad range of temperatures, from -196℃ to 37℃ (-320℉ to 99℉), with strict temperature control and traceability. Its Specialty Drug Distribution Unit (SDDU) provides a long-life shipping unit using liquid nitrogen in liquid phase for ultra-low temperature logistics.
